{"id":22501,"date":"2025-05-08T11:00:34","date_gmt":"2025-05-08T04:00:34","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=22501"},"modified":"2025-05-08T11:00:34","modified_gmt":"2025-05-08T04:00:34","slug":"penetrium-breaks-oncology-barriers-the-solution-to-cold-tumors-and-metastatic-cancer-unveiled-at-aacr-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=22501","title":{"rendered":"Penetrium\u2122 Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    \n
  • Penetrium\u2122 Achieves Historic Breakthrough <\/b><\/li>\n
  • Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy <\/b><\/li>\n
  • Presented at AACR 2025, Chicago<\/span><\/b><\/li>\n<\/ul>\n

    CHICAGO<\/span>, May 8, 2025 \/PRNewswire\/ — Hyundai Bioscience presented the results of its Penetrium\u2122 combination preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held in Chicago<\/span>.<\/span><\/p>\n

    \n<\/div>\n

    The studies established that the repeated failures of immunotherapy and antibody treatments in cold tumors are not primarily caused by genetic resistance, as traditionally believed, but by pseudo-resistance**\u2014a physical failure of infiltration resulting from extracellular matrix (ECM) stiffening. For the first time, Penetrium\u2122 has been shown to structurally overcome this barrier.<\/p>\n

    Correcting 80 Years of Misconception:\u00a0 The Real Problem Is Not Genetic Mutations\u2014It’s Pseudo-Resistance<\/b><\/p>\n

    For decades, the dominant theory behind cancer treatment failure centered around genetic mutations.\u00a0<\/p>\n

    However, Hyundai Bioscience’s latest findings show that the actual obstacle lies in stiffened ECM that prevents immune cells and antibodies from reaching the tumor core.<\/p>\n

    Penetrium\u2122 remodels the ECM, restoring infiltration pathways and enabling effective drug and immune cell access\u2014providing a fundamental solution to the cold tumor problem.<\/p>\n

    Penetrium\u2122 + Immunotherapy: Exceptional Results in Triple-Negative Breast Cancer (TNBC) Models<\/b><\/p>\n

    \u2460\u00a0In a TNBC mouse model, Penetrium\u2122 combined with anti-PD-1 therapy led to:<\/p>\n

      \n
    • A 48.3% reduction in tumor burden compared to anti-PD-1 monotherapy,<\/li>\n
    • Complete elimination of metastasis observed in the combination group, which remained present in the monotherapy group.<\/li>\n<\/ul>\n

      Significantly, necrosis was induced within 3 days of Penetrium\u2122 administration, and necrotic areas continued to grow with repeated dosing**\u2014a trend not observed in the control group.<\/p>\n

      \u2461\u00a0Penetrium\u2122 + Antibody Therapy:\u00a0 Complete Suppression of Lung Metastasis in a Metastatic Lung Cancer Model<\/p>\n

      In a metastatic lung cancer model:<\/p>\n

        \n
      • Bevacizumab monotherapy showed only 33% metastasis suppression,<\/li>\n
      • The Penetrium\u2122 combination group recorded 0% lung metastasis at 100 mg\/kg dosage.<\/li>\n<\/ul>\n

        Additionally, a marked decrease in MMP-9 and VEGF expression confirmed ECM normalization and the restoration of drug penetration routes at the molecular level.<\/p>\n

        \u2462\u00a0Penetrium\u2122 + Chemotherapy: Overcoming the Limitations of Paclitaxel<\/p>\n

        Paclitaxel monotherapy was found to paradoxically promote lung metastasis.\u00a0<\/p>\n

        However, when combined with Penetrium\u2122, metastatic lesion areas were reduced by over 70\u201380% compared to controls.<\/p>\n

        Furthermore, suppression of MMP-9 and restoration of E-cadherin demonstrated that Penetrium\u2122 not only enhances chemotherapy efficacy but also structurally blocks metastasis\u2014without additional toxicity.<\/p>\n

        Validated in Naturally Occurring Canine Mammary Cancer Model: \u00a0Stronger Responses Observed in Metastatic Tumors<\/b><\/p>\n

        In a naturally occurring canine mammary cancer model:<\/p>\n

          \n
        • The Penetrium\u2122 + POLYTAXEL\u00ae combination reduced primary tumor volume by up to 38.7%, compared to 21.1% with monotherapy,<\/li>\n
        • Metastatic lymph node lesions showed up to 78.99% tumor volume reduction.<\/li>\n<\/ul>\n

          Notably, metastatic lesions responded more strongly than primary tumors, challenging the long-standing notion that metastatic cancer is untreatable.<\/p>\n

          Proven Safety and Clinical Readiness<\/b><\/p>\n

          Penetrium\u2122 was administered at less than 9% of the NOAEL dose established in a 13-week GLP-compliant toxicity study.\u00a0<\/p>\n

          Its safety has also been verified in humans during a Phase 2 COVID-19 trial using the same API, niclosamide.<\/p>\n

          These results confirm Penetrium\u2122 is fully prepared for human clinical application.<\/p>\n

          Official Statement from Dr. Soo-Jung Kim<\/span>, Head of Research<\/b><\/p>\n

          “Penetrium\u2122 is the world’s first platform to structurally solve the infiltration failure that has caused repeated failure of immunotherapy and antibody therapy in cold tumors.\u00a0<\/p>\n

          Our combination study with immunotherapy exceeded expectations, and Hyundai Bioscience will soon initiate clinical trials of Penetrium\u2122 combinations for both TNBC and metastatic lung cancer.”\u00a0<\/p>\n

          \u2014 Dr. Soo-Jung Kim<\/span>, Head of Research, Hyundai Bioscience<\/p>\n

          Clinical Expansion Underway<\/b><\/p>\n

          Hyundai Bioscience is currently:<\/p>\n

            \n
          • Conducting a Phase 1 trial for prostate cancer in South Korea<\/span>,<\/li>\n
          • Preparing an investigator-initiated trial for acute myeloid leukemia (AML) in France<\/span>.<\/li>\n<\/ul>\n

            Penetrium\u2122: Launching a Tumor-Agnostic Cancer Treatment Platform<\/b><\/p>\n

            Penetrium ECM Remodeling Therapy\u2122 is evolving into a tumor-agnostic universal cancer treatment platform with applicability not only to TNBC and metastatic lung cancer, but also to pancreatic, gallbladder, ovarian cancers, and hematological malignancies such as AML.<\/p>\n

            This breakthrough research is the first to structurally resolve infiltration failure in cold tumors, while also proving that metastatic cancers can be effectively treated**\u2014a historic achievement in oncology.<\/p>\n

            About Hyundai Bioscience<\/b><\/p>\n

            Hyundai Bioscience is a global biotech company dedicated to developing innovative therapeutics for cancer, viral diseases, and rare conditions.<\/p>\n

            Through Penetrium ECM Remodeling Therapy\u2122, the company is opening a new era of universally applicable cancer treatment across all tumor types.<\/p>\n

            In the viral therapeutics space:<\/p>\n

              \n
            • Hyundai Bioscience successfully completed a Phase 2 clinical trial for COVID-19 in Korea,<\/li>\n
            • Is conducting a global Phase 2 dengue fever trial in Vietnam<\/span> in collaboration with DNDi (Drugs for Neglected Diseases initiative),<\/li>\n
            • And is developing influenza and avian influenza treatments in partnership with the NIH and global institutions.<\/li>\n<\/ul>\n

              Driven by its core belief that “There is no disease that cannot be treated,” Hyundai Bioscience continues to lead global innovation in cancer, antiviral, and rare disease therapeutics.<\/p>\n

              <\/div>","protected":false},"excerpt":{"rendered":"

              <\/p>\n\n\n\n
              \"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
                \n
              • Penetrium\u2122 Achieves Historic Breakthrough <\/b><\/li>\n
              • Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy <\/b><\/li>\n
              • Presented at AACR 2025, Chicago<\/span><\/b><\/li>\n<\/ul>\n

                CHICAGO<\/span>, May 8, 2025 \/PRNewswire\/ — Hyundai Bioscience presented the results of its Penetrium\u2122 combination preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held in Chicago<\/span>.<\/span><\/p>\n

                \n<\/div>\n

                The studies established that the repeated failures of immunotherapy and antibody treatments in cold tumors are not primarily caused by genetic resistance, as traditionally believed, but by pseudo-resistance**\u2014a physical failure of infiltration resulting from extracellular matrix (ECM) stiffening. For the first time, Penetrium\u2122 has been shown to structurally overcome this barrier.<\/p>\n

                Correcting 80 Years of Misconception:\u00a0 The Real Problem Is Not Genetic Mutations\u2014It’s Pseudo-Resistance<\/b><\/p>\n

                For decades, the dominant theory behind cancer treatment failure centered around genetic mutations.\u00a0<\/p>\n

                However, Hyundai Bioscience’s latest findings show that the actual obstacle lies in stiffened ECM that prevents immune cells and antibodies from reaching the tumor core.<\/p>\n

                Penetrium\u2122 remodels the ECM, restoring infiltration pathways and enabling effective drug and immune cell access\u2014providing a fundamental solution to the cold tumor problem.<\/p>\n

                Penetrium\u2122 + Immunotherapy: Exceptional Results in Triple-Negative Breast Cancer (TNBC) Models<\/b><\/p>\n

                \u2460\u00a0In a TNBC mouse model, Penetrium\u2122 combined with anti-PD-1 therapy led to:<\/p>\n

                  \n
                • A 48.3% reduction in tumor burden compared to anti-PD-1 monotherapy,<\/li>\n
                • Complete elimination of metastasis observed in the combination group, which remained present in the monotherapy group.<\/li>\n<\/ul>\n

                  Significantly, necrosis was induced within 3 days of Penetrium\u2122 administration, and necrotic areas continued to grow with repeated dosing**\u2014a trend not observed in the control group.<\/p>\n

                  \u2461\u00a0Penetrium\u2122 + Antibody Therapy:\u00a0 Complete Suppression of Lung Metastasis in a Metastatic Lung Cancer Model<\/p>\n

                  In a metastatic lung cancer model:<\/p>\n

                    \n
                  • Bevacizumab monotherapy showed only 33% metastasis suppression,<\/li>\n
                  • The Penetrium\u2122 combination group recorded 0% lung metastasis at 100 mg\/kg dosage.<\/li>\n<\/ul>\n

                    Additionally, a marked decrease in MMP-9 and VEGF expression confirmed ECM normalization and the restoration of drug penetration routes at the molecular level.<\/p>\n

                    \u2462\u00a0Penetrium\u2122 + Chemotherapy: Overcoming the Limitations of Paclitaxel<\/p>\n

                    Paclitaxel monotherapy was found to paradoxically promote lung metastasis.\u00a0<\/p>\n

                    However, when combined with Penetrium\u2122, metastatic lesion areas were reduced by over 70\u201380% compared to controls.<\/p>\n

                    Furthermore, suppression of MMP-9 and restoration of E-cadherin demonstrated that Penetrium\u2122 not only enhances chemotherapy efficacy but also structurally blocks metastasis\u2014without additional toxicity.<\/p>\n

                    Validated in Naturally Occurring Canine Mammary Cancer Model: \u00a0Stronger Responses Observed in Metastatic Tumors<\/b><\/p>\n

                    In a naturally occurring canine mammary cancer model:<\/p>\n

                      \n
                    • The Penetrium\u2122 + POLYTAXEL\u00ae combination reduced primary tumor volume by up to 38.7%, compared to 21.1% with monotherapy,<\/li>\n
                    • Metastatic lymph node lesions showed up to 78.99% tumor volume reduction.<\/li>\n<\/ul>\n

                      Notably, metastatic lesions responded more strongly than primary tumors, challenging the long-standing notion that metastatic cancer is untreatable.<\/p>\n

                      Proven Safety and Clinical Readiness<\/b><\/p>\n

                      Penetrium\u2122 was administered at less than 9% of the NOAEL dose established in a 13-week GLP-compliant toxicity study.\u00a0<\/p>\n

                      Its safety has also been verified in humans during a Phase 2 COVID-19 trial using the same API, niclosamide.<\/p>\n

                      These results confirm Penetrium\u2122 is fully prepared for human clinical application.<\/p>\n

                      Official Statement from Dr. Soo-Jung Kim<\/span>, Head of Research<\/b><\/p>\n

                      “Penetrium\u2122 is the world’s first platform to structurally solve the infiltration failure that has caused repeated failure of immunotherapy and antibody therapy in cold tumors.\u00a0<\/p>\n

                      Our combination study with immunotherapy exceeded expectations, and Hyundai Bioscience will soon initiate clinical trials of Penetrium\u2122 combinations for both TNBC and metastatic lung cancer.”\u00a0<\/p>\n

                      \u2014 Dr. Soo-Jung Kim<\/span>, Head of Research, Hyundai Bioscience<\/p>\n

                      Clinical Expansion Underway<\/b><\/p>\n

                      Hyundai Bioscience is currently:<\/p>\n

                        \n
                      • Conducting a Phase 1 trial for prostate cancer in South Korea<\/span>,<\/li>\n
                      • Preparing an investigator-initiated trial for acute myeloid leukemia (AML) in France<\/span>.<\/li>\n<\/ul>\n

                        Penetrium\u2122: Launching a Tumor-Agnostic Cancer Treatment Platform<\/b><\/p>\n

                        Penetrium ECM Remodeling Therapy\u2122 is evolving into a tumor-agnostic universal cancer treatment platform with applicability not only to TNBC and metastatic lung cancer, but also to pancreatic, gallbladder, ovarian cancers, and hematological malignancies such as AML.<\/p>\n

                        This breakthrough research is the first to structurally resolve infiltration failure in cold tumors, while also proving that metastatic cancers can be effectively treated**\u2014a historic achievement in oncology.<\/p>\n

                        About Hyundai Bioscience<\/b><\/p>\n

                        Hyundai Bioscience is a global biotech company dedicated to developing innovative therapeutics for cancer, viral diseases, and rare conditions.<\/p>\n

                        Through Penetrium ECM Remodeling Therapy\u2122, the company is opening a new era of universally applicable cancer treatment across all tumor types.<\/p>\n

                        In the viral therapeutics space:<\/p>\n

                          \n
                        • Hyundai Bioscience successfully completed a Phase 2 clinical trial for COVID-19 in Korea,<\/li>\n
                        • Is conducting a global Phase 2 dengue fever trial in Vietnam<\/span> in collaboration with DNDi (Drugs for Neglected Diseases initiative),<\/li>\n
                        • And is developing influenza and avian influenza treatments in partnership with the NIH and global institutions.<\/li>\n<\/ul>\n

                          Driven by its core belief that “There is no disease that cannot be treated,” Hyundai Bioscience continues to lead global innovation in cancer, antiviral, and rare disease therapeutics.<\/p>\n

                          <\/div>\n

                          <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-22501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22501"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22501\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}